scholarly journals Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

2012 ◽  
Vol 70 (10) ◽  
pp. 774-779 ◽  
Author(s):  
Valéria Coelho Santa Rita Pereira ◽  
Fabíola Rachid Malfetano ◽  
Isabella D'Andrea Meira ◽  
Letícia Fêzer de Souza ◽  
Assuncion Martinez Liem ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Treatment Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Response To Treatment ◽  
Clinical Criteria ◽  
Significant Difference ◽  
One Year ◽  
Multiple Sclerosis Patients

INTRODUCTION: Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE: It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among relapsing-remitting multiple sclerosis (RRMS) patients. METHODS: We analyzed treatment response to IFNb and GA in ninety-one RRMS patients followed for at least one year. Clinical response was established by clinical criteria based on relapses, disability progression or both. RESULTS: We observed a proportion of nonresponders, ranging from 3.3 to 42.9%, depending on the stringency of the criteria used. CONCLUSIONS: Our sample of Brazilian patients with MS has similarities when compared to other studies and there was no statistically significant difference regarding age, gender, ethnicity or disease duration between responders and nonresponders.

Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

2018 ◽  
Vol 39 (8) ◽  
pp. 1423-1430 ◽  
Author(s):  
Bonaventura Casanova ◽  
Laura Lacruz ◽  
María Luisa Villar ◽  
José Andrés Domínguez ◽  
María Carcelén Gadea ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

2006 ◽  
Vol 12 (3) ◽  
pp. 281-286 ◽  
Author(s):  
E Portaccio ◽  
V Zipoli ◽  
G Siracusa ◽  
S Sorbi ◽  
M P Amato
Keyword(s):  
Multiple Sclerosis ◽  
Relapse Rate ◽  
Interferon Beta ◽  
Clinical Criteria ◽  
Predictors Of Response ◽  
Lower Baseline ◽  
Disability Status ◽  
Relapsing Remitting ◽  
One Year ◽  
Relapsing Remitting Multiple Sclerosis

We assessed the proportion and potential predictors of response to interferon-beta (IFNβ) therapy in relapsing-remitting (RR) multiple sclerosis (MS) patients, comparing different definitions of response: a) lower relapse rate during therapy compared to the year and the two years before therapy, b) reduction of relapse rate during therapy of at least 30% compared to the two years before therapy, c) no relapse during treatment, d) no progression on the Expanded Disability Status Scale (EDSS). Among 147 RR patients treated for at least one year, 33 received IFNβ-1b subcutaneously (SC) (Betaferon), 59 IFNβ-1a intramuscularly (Avonex) and 55 IFNβ-1a SC (Rebif). Using definitions a), b) and d), 72%, 73% and 73% patients, respectively, were considered responders. Forty-four per cent of our patients were completely relapse free. In the logistic regression model, using definitions a) and b), a higher relapse rate in the two years preceding the therapy turned out to be a significant predictor of response. Considering definition c), lower baseline relapse rate was associated with a more favourable response.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

2018 ◽  
Vol 394 ◽  
pp. 127-131 ◽  
Author(s):  
Brian C. Healy ◽  
Bonnie I. Glanz ◽  
Jonathan D. Zurawski ◽  
Maria Mazzola ◽  
Tanuja Chitnis ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate

2011 ◽  
Vol 65 (3) ◽  
pp. 164-169 ◽  
Author(s):  
Hayrettin Tumani ◽  
Jan Kassubek ◽  
Mohammed Hijazi ◽  
Vera Lehmensiek ◽  
Alexander Unrath ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Glatiramer Acetate ◽  
Th2 Cytokines ◽  
Multiple Sclerosis Patients

scholarly journals Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3324
Author(s):  
Diana Ferraro ◽  
Sara De Biasi ◽  
Anna Maria Simone ◽  
Riccardo Orlandi ◽  
Milena Nasi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Safety Data ◽  
Absolute Number ◽  
Clinical Relapse ◽  
Inkt Cells ◽  
Time Points ◽  
Cell Counts ◽  
Significant Difference ◽  
One Year ◽  
Multiple Sclerosis Patients

The altered numbers and functions of cells belonging to immunoregulatory cell networks such as T regulatory (Tregs) and invariant Natural Killer T (iNKT) cells have been reported in Multiple Sclerosis (MS), an immune-mediated disease. We aimed to assess the frequencies of Tregs and iNKT cells in MS patients throughout a one-year treatment with fingolimod (FTY) and to correlate immunological data with efficacy and safety data. The percentage of Tregs (defined as Live Dead-CD3 + CD4 + FoxP3 + CD25++/CD127− cells) increased steadily throughout the year, while there was no significant difference in the absolute number or percentage of iNKT cells (defined as CD3 + CD14−CD19− Vα24-Jα18 TCR+ cells). However, out of all the iNKT cells, the CD8+ iNKT and CD4−CD8− double-negative (DN) cell percentages steadily increased, while the CD4+ iNKT cell percentages decreased significantly. The mean percentage of CD8+ T cells at all time-points was lower in patients with infections throughout the study. The numbers and percentages of DN iNKT cells were more elevated, considering all time-points, in patients who presented a clinical relapse. FTY may, therefore, exert its beneficial effect in MS patients through various mechanisms, including the increase in Tregs and in iNKT subsets with immunomodulatory potential such as CD8+ iNKT cells. The occurrence of infections was associated with lower mean CD8+ cell counts during treatment with FTY.

Sign in / Sign up

Export Citation Format

Share Document